Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dicyclol
- Development stage
- Phase 1
- Lead developer
- Renji Hospital
- Administration
- Oral
01
Overview
Dicyclol is a drug currently undergoing a Phase III clinical trial for the treatment of acute drug-induced liver injury (DILI). The intervention in the trial is described as Dicyclic alcohol (25 mg/tablet). Beyond its investigation for DILI, specific details regarding its mechanism of action, chemical structure, or developer are not readily available in public databases, and it should not be confused with Dicyclomine, an anticholinergic agent used for gastrointestinal disorders, which has not been linked to liver injury.
- Other names
- Dicyclic alcohol
02
Targets
Bradykinin B2 receptorH (Histamine receptors)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)
Beyond the preview
Go deeper on dicyclol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dicyclol.